Programmed death‐1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis

A. Singh, A. Mohan, Aprajit B Dey, Dipendra K. Mitra
{"title":"Programmed death‐1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis","authors":"A. Singh, A. Mohan, Aprajit B Dey, Dipendra K. Mitra","doi":"10.1111/cei.12871","DOIUrl":null,"url":null,"abstract":"Optimal T cell activation is vital for the successful resolution of microbial infections. Programmed death‐1 (PD‐1) is a key immune check‐point receptor expressed by activated T cells. Aberrant/excessive inhibition mediated by PD‐1 may impair host immunity to Mycobacterium tuberculosis infection, leading to disseminated disease such as miliary tuberculosis (MTB). PD‐1 mediated inhibition of T cells in pulmonary tuberculosis and TB pleurisy is reported. However, their role in MTB, particularly at the pathological site, remains to be addressed. The objective of this study was to investigate the role of PD‐1–PD‐ligand 1 (PD‐L1) in T cell responses at the pathological site from patients of TB pleurisy and MTB as clinical models of contained and disseminated forms of tuberculosis, respectively. We examined the expression and function of PD‐1 and its ligands (PD‐L1–PD‐L2) on host immune cells among tuberculosis patients. Bronchoalveolar lavage‐derived CD3 T cells in MTB expressed PD‐1 (54·2 ± 27·4%, P ≥ 0·0009) with significantly higher PD‐1 ligand‐positive T cells (PD‐L1: 19·8 ± 11·8%; P ≥ 0·019, PD‐L2: 12·6 ± 6·2%; P ≥ 0·023), CD19+ B cells (PD‐L1: 14·4 ± 10·4%; P ≥ 0·042, PD‐L2: 2·6 ± 1·43%; not significant) and CD14+ monocytes (PD‐L1: 40·2 ± 20·1%; P ≥ 0·047, PD‐L2: 22·4 ± 15·6%; P ≥ 0·032) compared with peripheral blood (PB) of MTB and healthy controls. The expression of PD‐1 was associated with a diminished number of cells producing effector cytokines interferon (IFN)‐γ, tumour necrosis factor (TNF)‐α, interleukin (IL)−2 and elevated apoptosis. Locally accumulated T cells were predominantly PD‐1+–PD‐L1+, and blocking this pathway restores the protective T cell response. We conclude that M. tuberculosis exploits the PD‐1 pathway to evade the host immune response by altering the T helper type 1 (Th1) and Th2 balance at the pathological site of MTB, thereby favouring disease dissemination.","PeriodicalId":10179,"journal":{"name":"Clinical & Experimental Immunology","volume":"79 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Experimental Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/cei.12871","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 16

Abstract

Optimal T cell activation is vital for the successful resolution of microbial infections. Programmed death‐1 (PD‐1) is a key immune check‐point receptor expressed by activated T cells. Aberrant/excessive inhibition mediated by PD‐1 may impair host immunity to Mycobacterium tuberculosis infection, leading to disseminated disease such as miliary tuberculosis (MTB). PD‐1 mediated inhibition of T cells in pulmonary tuberculosis and TB pleurisy is reported. However, their role in MTB, particularly at the pathological site, remains to be addressed. The objective of this study was to investigate the role of PD‐1–PD‐ligand 1 (PD‐L1) in T cell responses at the pathological site from patients of TB pleurisy and MTB as clinical models of contained and disseminated forms of tuberculosis, respectively. We examined the expression and function of PD‐1 and its ligands (PD‐L1–PD‐L2) on host immune cells among tuberculosis patients. Bronchoalveolar lavage‐derived CD3 T cells in MTB expressed PD‐1 (54·2 ± 27·4%, P ≥ 0·0009) with significantly higher PD‐1 ligand‐positive T cells (PD‐L1: 19·8 ± 11·8%; P ≥ 0·019, PD‐L2: 12·6 ± 6·2%; P ≥ 0·023), CD19+ B cells (PD‐L1: 14·4 ± 10·4%; P ≥ 0·042, PD‐L2: 2·6 ± 1·43%; not significant) and CD14+ monocytes (PD‐L1: 40·2 ± 20·1%; P ≥ 0·047, PD‐L2: 22·4 ± 15·6%; P ≥ 0·032) compared with peripheral blood (PB) of MTB and healthy controls. The expression of PD‐1 was associated with a diminished number of cells producing effector cytokines interferon (IFN)‐γ, tumour necrosis factor (TNF)‐α, interleukin (IL)−2 and elevated apoptosis. Locally accumulated T cells were predominantly PD‐1+–PD‐L1+, and blocking this pathway restores the protective T cell response. We conclude that M. tuberculosis exploits the PD‐1 pathway to evade the host immune response by altering the T helper type 1 (Th1) and Th2 balance at the pathological site of MTB, thereby favouring disease dissemination.
程序性死亡- 1+ T细胞抑制军性结核病理部位的效应T细胞
最佳的T细胞激活对于成功解决微生物感染至关重要。程序性死亡- 1 (PD - 1)是一种由活化T细胞表达的关键免疫检查点受体。PD‐1介导的异常/过度抑制可能损害宿主对结核分枝杆菌感染的免疫力,导致播散性疾病,如军旅结核(MTB)。PD‐1介导的T细胞抑制在肺结核和结核胸膜炎中被报道。然而,它们在MTB中的作用,特别是在病理部位,仍然有待解决。本研究的目的是研究PD‐1 - PD‐配体1 (PD‐L1)在结核胸膜炎和结核分枝杆菌(MTB)患者病理部位T细胞反应中的作用,这些结核分枝杆菌分别作为包含型和播散型结核的临床模型。我们检测了PD‐1及其配体(PD‐L1-PD‐L2)在肺结核患者宿主免疫细胞上的表达和功能。支气管肺泡灌洗来源的CD3 T细胞在MTB中表达PD‐1(54.2±27.4%,P≥0.0009),PD‐1配体阳性T细胞显著升高(PD‐L1: 19.8±11.8%;P≥0.019,pd‐l2: 12.6±6.2%;P≥0.023),CD19+ B细胞(PD‐L1: 14.4±10.4%;P≥0.042,pd‐l2: 2.6±1.43%;无统计学意义)和CD14+单核细胞(PD‐L1: 40.2±20.1%;P≥0.047,pd‐l2: 22.4±15.6%;P≥0·032),与对照组外周血(PB)比较。PD‐1的表达与产生效应细胞因子干扰素(IFN)‐γ、肿瘤坏死因子(TNF)‐α、白细胞介素(IL)−2的细胞数量减少和细胞凋亡升高有关。局部积累的T细胞主要是PD‐1+ -PD‐L1+,阻断这一途径可恢复保护性T细胞反应。我们得出结论,结核分枝杆菌利用PD‐1途径通过改变结核分枝杆菌病理部位的辅助性T型1 (Th1)和Th2平衡来逃避宿主免疫应答,从而有利于疾病传播。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信